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Increased attention to human papillomavirus (HPV)-associated cancers in light
of the recent release of an HPV vaccine, as well as increased availability of cancer
registry data that now include reporting from a large proportion of the US popu-
lation, prompted the current assessment of HPV-associated cancers. This article
describes methods used to assess the burden of HPV-associated cervical, vulvar,
vaginal, penile, anal, and oral cavity/oropharyngeal cancers in the United States
during 1998 through 2003 using cancer registry data, and it provides a brief over-
view of the epidemiology of these cancers. Cancer 2008;113(10 suppl):2841–54.
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P ersistent infection with the human papillomavirus (HPV) is con-sidered to be a cause of nearly all cervical cancer.1 It is believed
that HPV also is associated with approximately 90% of anal cancers;
40% of penile, vaginal, and vulvar cancers; 25% of oral cavity can-
cers; and 35% of oropharyngeal cancers.2,3 A quadrivalent HPV vac-
cine that protects against HPV type 6 (HPV-6), HPV-11, HPV-16, and
HPV-18 has been approved for use in the United States for females
ages 9 years to 26 years, and a bivalent vaccine that protects against
HPV-16 and HPV-18 currently is under review by the US Food and
Drug Administration. It has been demonstrated that the HPV vaccine
reduces the incidence of cervical, vaginal, and vulvar precancers, offer-
ing hope for the reduction in incidence of these diseases and the corre-
sponding invasive cancers among women.4,5 Current studies are
assessing the efficacy of the vaccine on HPV-associated disease in
men.6 Close surveillance of these cancers will be necessary to ensure
that high-risk populations are being reached by vaccination programs.
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Increased attention to HPV-associated cancers in
light of the recent release of the vaccine, as well as
increased availability of cancer registry data,
prompted the current Supplement of Cancer titled
‘‘Assessing the Burden of HPV-Associated Cancers in
the United States’’ (ABHACUS). The major purposes
of this Supplement are to assess the current burden
of anogenital and oropharyngeal cancers associated
with HPV within the United States and to provide a
baseline for monitoring future trends in HPV-asso-
ciated cancers. This article describes methods used
to assess the burden of HPV-associated cancers in
the United States—methods that are common to sev-
eral articles in the Supplement. This article describes
the data sources, case definitions, variables, and ana-
lytic methods of descriptive epidemiologic articles
that are included in this Supplement, and it provides
an overall picture of the burden of HPV-associated
cancers.
Data Sources: Cancer Registry and Mortality
Surveillance Systems
We used cancer incidence data from population-
based cancer registries that participate in the Center
for Disease Control and Prevention’s (CDC’s) National
Program of Cancer Registries (NPCR) and the
National Cancer Institute’s (NCI’s) Surveillance, Epi-
demiology, and End Results Program (SEER).7-9 The
SEER Program began in 1973 as a result of the
National Cancer Act. SEER began collecting and pub-
lishing cancer incidence and survival data from 5
state cancer registries and from 4 metropolitan
population-based cancer registries covering approxi-
mately 10% of the US population. Over time, the pro-
gram has expanded its coverage of the population to
include 9 states and 6 metropolitan areas, in total
covering 26% of the population. Recognizing the
need for more complete local, state, regional, and
national cancer incidence data, Congress established
the NPCR in 1992.10 The NPCR now supports cancer
registries in 45 states, the District of Columbia, and 3
US territories, and it covers 96% of the population
(Fig. 1). NPCR and SEER provide dual support to 4
statewide cancer registries. These SEER metropoli-
tan-area and special population cancer registries
report their incidence data to both NCI and to the
NPCR statewide cancer registries in their respective
states. Together, NPCR and SEER now collect cancer
incidence data for the entire US population. Both
NPCR data and SEER data are collected and reported
by use of standard data items and uniform codes
and procedures, as documented by the North Ameri-
can Association of Central Cancer Registries
(NAACCR).11 Registries in each program also collect
additional data items as required by their funding
FIGURE 1. States and metropolitan areas supported by the National Program of Cancer Registries, which is administered through the Centers for Disease
Control and Prevention, and the Surveillance, Epidemiology, and End Results Program, which is administered through the National Cancer Institute.
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agencies. Reportable cancers include in situ or inva-
sive primary cancers of all sites except in situ cancer
of the cervix, for which collection stopped in 1996.12
Basal and squamous cell carcinomas (SCCs) of the
skin are also excluded, with the exception of those
on the skin of the genital organs. Cancer cases were
coded according to the version of the International
Classification of Diseases for Oncology (ICD-O) that
was in use at the time of diagnosis. The second edi-
tion of the ICD-O (ICD-O-2) was used during the di-
agnosis years from 1998 through 2000, and the third
edition of the ICD-O (ICD-O-3) was used for the di-
agnosis years from 2001 through 2003; the data from
1998 through 2000 were converted to ICD-O-3
codes.13-16
Hospitals and other facilities that diagnose or
treat cancer collect and report cancer incidence data
to central cancer registries (Fig. 2). SEER registries
also collect follow-up information for determination
of cancer survival statistics. Medical and demo-
graphic information for cancer cases is obtained pri-
marily from medical records. Although the majority
of cancer cases still are reported by hospitals, data
increasingly are obtained from nonhospital sources,
such as pathology laboratories, radiation facilities,
freestanding surgical centers, long-term care facil-
ities, and physicians’ offices. A small percentage
(5%) of medical and demographic information is
obtained solely from death certificates. At the central
cancer registries, staff consolidates the data received
from hospitals and other facilities and use death cer-
tificate data to update the vital status of cases al-
ready in the registry.17 These tasks are completed
before the data are submitted to either or both fed-
eral agencies (Fig. 2). Central cancer registries submit
deidentified data to these agencies to be used for
publication in statistical and analytic summaries and
for release in restricted datasets for research.
We used cancer mortality data obtained from
death certificates that contained demographic infor-
mation and cause of death throughout the United
States and that were coded according to the version
of the ICD-O that was in use at the time of death.
These data are reported to state vital statistics offices
and consolidated into a national database by the
CDC through the National Vital Statistics System.18
The underlying cause of cancer death is coded to the
primary cancer site according to the version of the
International Classification of Diseases (ICD) in use
at the time of death and is grouped for maximum
comparability among ICD versions.13,14,19 The US
Standard Certificate of Death, which is used as a
model by the state, was revised in 2003.20 This report
includes data from 4 states (California, Idaho, Mon-
tana, and New York), which implemented the 2003
revision of the US Standard Certificate of Death in
2003. For the remaining 46 States and the District of
Columbia that collected and reported death data in
2003, the data were based on the 1989 revision of the
US Standard Certificate of Death. The 2003 revision
of the US Standard Certificate of Death allows the
reporting of more than 1 race (multiple races).20
Data Sources: Databases Used in This Supplement
Cancer incidence data were included in this Supple-
ment if the cancer registry met the following publica-
tion criteria for the United States Cancer Statistics
(USCS) report for all years from 1998 through 2003:
Case ascertainment was at least 90% of expected
cases (with the expected cases estimated by using
methods developed by NAACCR), 97% of cases
passed a standard set of computerized edits, 5%
of cases were reported by death certificate only, 5%
of cases were missing information on race, 3% of
cases were missing information on sex, and 3% of
cases were missing information on age.7,21
Although NPCR and SEER registries currently
(since 1998) cover 100% of the US population, only
registries that meet USCS publication criteria for all
6 years were included in this analysis to ensure that
high-quality data were used. NPCR and SEER data
from 39 registries met the data quality criteria for
inclusion in this report. Figure 3 shows a map of the
cancer registries that are included in our database.
FIGURE 2. Collection and consolidation of data from patient facilities to
federal cancer programs. The National Program of Cancer Registries (NPCR)
is administered through the Centers for Disease Control and Prevention
(available at: http://www.cdc.gov/cancer/npcr/ accessed on March 3, 2008).
The Surveillance, Epidemiology, and End Results Program (SEER) is adminis-
tered through the National Cancer Institute (available at: http://seer.cancer.
gov/ accessed on March 3, 2008). Central cancer registries also submit
data to the North American Association of Central Cancer Registries, which
is an association of population-based cancer registries.
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These registries cover approximately 83% of the US
population: 84% of whites, 74% of blacks, 90% of
Asian/Pacific Islanders (APIs), and 91% of Hispanics.
Regionally, 98% of the population in the Northeast
and Midwest are covered, 63% of the South is cov-
ered, and 88% of the West is covered. Because SEER
has been in existence since 1973, analyses of treat-
ment, trends and survival, which require data over a
longer period of time, were limited to SEER data
only.
NPCR data for this Supplement were reported to
the CDC as of January 31, 2006. SEER data were
reported to the NCI as of November 2005 and were
made available through the SEER Program limited-
use data file that was released in April 2006.22 Data
from states that are supported by both NPCR and
SEER are presented as reported to the CDC as of
January 2006 unless stated otherwise.7
Variation by race (white, black, and API) and His-
panic ethnicity were examined extensively for this
Supplement. NPCR and SEER obtain information on
race and Hispanic ethnicity from medical records.
Identification of Hispanic ethnicity for cancer cases
was augmented by a hierarchical algorithm that used
race, birthplace, sex, maiden name, and surname.23
The CDC and other national partners have estab-
lished a strategy to improve identification of Ameri-
can Indian/Alaska Native (AI/AN) cases; however,
data on AI/ANs are not presented as a separate cate-
gory in this Supplement, because such an identifica-
tion strategy was not complete for all years in our
dataset.24
Cancer death data for the years 1998 through
2003 are based on records of deaths that occurred
from 1998 through 2003 for which the records were
received as of February 28, 2005. Cancer deaths that
were diagnosed before 1999 were recoded to ICD-O-3
categories. Because the 2003 revision of the US
Standard Certificate of Death allows for the selection
of multiple races, multiracial decedents were recoded
to a single race (either white, black, AI/AN, or API)
according to their combination of races, Hispanic or-
igin, sex, and age indicated on the death certificate.25
The population denominator data for calculating
cancer incidence and mortality rates were obtained
from the 2000 US Census and modified by SEER for
the purpose of improving the accuracy of rates for
the population of Hawaii.26
FIGURE 3. States by US Census region and division (total population coverage, 83%). Population coverage by region: Northeast, 98%; Midwest, 98%; South,
63%; West, 88%. States that did not meet the inclusion criteria were not included because they did not meet standards for high-quality data collection for all
years from 1998 through 2003 (see Havener, 200421). USCS indicates United States Cancer Statistics.
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Case Definition and Explanation of Potential
Association With HPV
This Supplement highlights the 6 cancer sites (cervi-
cal, vulvar, vaginal, anal, penile, and oral cavity/oro-
pharynx) that are considered to have sufficient
evidence for HPV as a carcinogen (Table 1).27 Accord-
ing to Parkin and Bray, the strict definition of popula-
tion attributable fraction needs to be modified when
noncervical HPV-associated cancers are considered,
because the prevalence of HPV infection among indi-
viduals in the control group (cancer-free) at the parti-
cular anatomic site currently is unknown.2,28 The
prevalence of HPV DNA detection varies considerably
by type of assay and detection method. For the non-
cervical HPV-associated cancers, the percentage at-
tributable fraction refers to the general percent of
those cancers in which HPV DNA can be demon-
strated in tumor cells, or HPV prevalence. For this
Supplement, attributable fractions were based on the
work by Parkin with an update on oral cavity and oro-
pharyngeal cancers based on a systematic review by
Kreimer (Table 1).2,3 The attributable fractions may be
considered by some to be a conservative estimate of
attributable fraction (or HPV DNA prevalence) for
many of the sites. Taking into account a lack of sys-
tematic reviews of HPV DNA prevalence in most of the
noncervical cancers, the different methodologies for
determining HPV DNA prevalence and the geographic
variability in the HPV-type distribution of the cancers,
we believed that using this conservative estimate was
most appropriate. We realize that the attributable frac-
tion may change with additional research on HPV
detection methods and systematic reviews. Thus,
when we describe the burden, we are not taking into
account the attributable fraction for each site. Instead,
we are reporting the burden of potentially HPV-asso-
ciated cancers, which were defined by focusing on
specific sites and specific histologies, and we refer to
these as ‘HPV-associated.’ This article and others that
describe the burden of HPV-associated cancers in this
Supplement do not attempt to provide actual esti-
mates of the attributable fraction of HPV in these can-
cers but provide basic information about cancers in
sites that are believed to be primarily HPV-associated.
The information about burden provided in this Supple-
ment can be compared over time by using the standar-
dized criteria provided—independent of any variation
that may occur over time in the estimated attributable
fraction.
We identified 5 HPV-associated sites for females
(cervix, vulva, vagina, anus, and oral cavity/orophar-
ynx) and 3 sites for males (penis, anus, and oral cav-
ity/oropharynx). Cases were grouped according to
the ICD-O-3 site categories listed in Table 2. Specific
HPV-associated subsites were identified for cancers
of the oral cavity and oropharynx.29 To further iden-
tify those cancers most likely to be HPV-associated,
we also limited analyses by ICD-O-3 histology code
(Table 3). Cervical cancer was limited to carcinomas
(ICD-O-3 histology codes 8010-8671 and 8940-
8941).1,30 In all other sites, SCCs are most likely to be
associated with HPV; thus, HPV-associated cancers of
the vulva, vagina, penis, anus, and oral cavity/oro-
pharynx were defined as SCCs (ICD-O-3 histology
codes 8050-8084 and 8120-8131).2 Analyses that were
limited by histology (or that described the distribu-
tion of histology) were confined to tumors with
microscopically confirmed histology (Fig. 4).
Some articles in this Supplement examine the
burden of in situ cancer (behavior code of 2 in the
NPCR and SEER databases). Vulvar, vaginal, and anal
intraepithelial neoplasia lesions (specifically, vulvar
intraepithelial neoplasia 3, vaginal intraepithelial
neoplasia 3, and anal intraepithelial neoplasia 3)
with an ICD-O-3 histology code of 8077 and behavior
code of 2 are required to be reported by NPCR and
TABLE 1






HPV-16 and HPV-18 Reference(s)
Cervix 100 Parkin & Bray 20062 70 Munoz 200449
Vagina 40 Parkin & Bray 20062 80 Daling 200250
Vulva 40 Parkin & Bray 20062 80 Trimble 199651; Iwasawa 199752
Penis 40 Parkin & Bray 20062 63 Rubin 200153
Anus 90 Parkin & Bray 20062 92 Daling 200454; Frisch 199955
Oral cavity 25 Kreimer 20053 95 Kreimer 20053
Oropharynx 35 Kreimer 20053 89 Kreimer 20053
HPV indicates human papillomavirus.
*This table was adapted from Parkin & Bray 20062 with updates based on Kreimer 2005.3 See text for further discussion of HPV-attributable fractions.
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SEER registries but are not collected uniformly; thus,
they were excluded from all analyses.31 It is believed
generally that these lesions are associated with
HPV.32 We have chosen to refer to these lesions by
using Arabic numerals in accordance with World
Health Organization terminology (eg, cervical intrae-
pithelial neoplasia is referred to as CIN-3 rather than
CIN-III). The collection of penile intraepithelial neo-
plasia (PIN-3) has not been required by NPCR and
SEER since 2000.31
TABLE 2
Definitions for Site Recode and Histology Codes











All carcinomas (squamous cell, adenocarcinoma,
adenosquamous/glassy cell, small cell
neuroendocrine, other and unspecified)
Vagina C52 Squamous cell carcinomasy
Vagina, NOS C52.9




Overlapping lesion of vulva C51.8
Vulva, NOS C51.9




Overlapping lesion of rectum, anus and anal canal C21.8
Rectum{ C20.9
Penis C60 Squamous cell carcinomas
Prepuce (foreskin) C60.0
Glans penis C60.1
Body of penis C60.2
Overlapping lesion of penis C60.8
Penis, NOS C60.9
Base of tongue and lingual tonsil Squamous cell carcinomas
Base of tongue, NOS C01.9
Lingual tonsil C02.4
Tonsil (including Waldeyer ring) Squamous cell carcinomas
Tonsillar fossa C09.0
Tonsillar pillar C09.1
Overlapping lesion of tonsil C09.8
Tonsil, NOS C09.9
Waldeyer ring C14.2
Other oropharynx, potentially HPV-associated Squamous cell carcinomas
Overlapping lesion of tongue C02.8
Lateral wall of oropharynx C10.2
Overlapping lesion of oropharynx C10.8
Oropharynx, NOS C10.9
Pharynx, NOS C14.0
Overlapping lesion of lip, oral cavity, and pharynx C14.8
ICD-O-3, International Classification of Diseases for Oncology, 3rd Edition; NOS, not otherwise specified; HPV, human papillomavirus.
*All carcinomas defined as ICD-O-3 histology codes 8010-8671, 8940-8941. Squamous cell carcinomas (SCCs) defined as ICD-O-3 histology codes 8050-8084,
8120-8131.
yThis article and others in the current supplement that examined National Program of Cancer Registries/Surveillance, Epidemiology, and End Results excluded
code 8077/2 (intraepithelial neoplasia 3) for vaginal, vulvar, and anal cancers.
{SCCs of the rectum are included. Because the rectum is made up of glandular cells and not squamous cells, we assumed that microscopically confirmed rectal
SCCs were miscoded to the rectum or were overlapping anal lesions and treated these cancers like anal cancers (see Joseph 200736).
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Anal and rectal SCCs were considered to be
HPV-associated cancers for the purpose of our analy-
ses. Anal SCCs are associated strongly with HPV.33-36
The majority of rectal cancers are adenocarcinomas,
which are not considered HPV-associated. True rectal
SCCs are rare, but they generally may be HPV-asso-
ciated; overlapping SCCs of the anus also may be
misclassified as rectal SCCs.36,37 These cancers were
included in our analyses of HPV-associated anal can-
cers (Table 2).34,38 After we limited the analyses to
microscopically confirmed SCCs, only 1.9% of inva-
sive rectal cancers and 2.9% of all in situ rectal can-
cers were considered HPV-associated, whereas 77.9%
of invasive anal cancers and 65.5% of in situ anal
cancers were considered HPV-associated.
Oral cavity and oropharyngeal sites that are con-
sidered HPV-associated were grouped into 3 major
anatomic subsites: the tonsil, including the Waldeyer
ring; the base of tongue and lingual tonsil; and other
HPV-associated sites within the oropharynx (Table
2). These sites were identified as having the strongest
correlation with HPV by the scientific writing group
on oral cavity and oropharyngeal cancers on the ba-
sis of existing literature and expert advice.29
Statistical Analysis
Age-adjusted incidence and death rates were calcu-
lated per 100,000 persons unless specified otherwise.
Rates were age-adjusted to the 2000 US standard
population by the direct method using 19 age groups
(ages <1 year, 1-4 years, 5-9 years, 10-14 years, 15-
19 years, . . . 85 years).39 Cancer cases with
unknown sex or age were excluded from all analyses.
Incidence and death rates and 95% confidence
intervals were calculated in SEER*Stat (version 6.2.4),
a statistical software package that was developed by
TABLE 3
General Histologic Classification of Invasive and In Situ Cancers
Examined in the Current Supplement ‘‘Assessing the Burden of
HPV-Associated Cancers in the United States’’*
Histology ICD-O-3 Codes
Carcinomas 8010-8671, 8940-8941
Squamous cell and transitional cell 8050-8084, 8120-8131




Adenocarcinomas 8140-8149, 8160-8162, 8190-8221,8260-
8337, 8350-8551, 8570-8576, 8940-8941
Adenosquamous and glassy cell 8560, 8015
Small cell/neuroendocrine 8013, 8041-8045, 8240-8246
Other specified carcinomas 8014, 8030-8040, 8046, 8090-8110, 8150-
8157, 8170-8180, 8230-8239, 8247-8255,
8340-8347, 8561-8562, 8580-8671
Unspecified carcinomas 8010-8012, 8020-8022
Noncarcinomas All remaining values
ICD-O-3 indicates International Classification of Diseases for Oncology, 3rd Edition.
*This article and others in the current supplement that examined National Program of Cancer Regis-
tries/ Surveillance, Epidemiology, and End Results excluded code 8077/2 (intraepithelial neoplasia 3)
for vaginal, vulvar, and anal cancers.
FIGURE 4. Invasive cancers that were examined in the Assessing the Burden of HPV-Associated Cancers in the United States (ABHACUS) supplement: United
States, 1998 through 2003. Data are from population-based cancer registries that participate in the National Program of Cancer Registries (NPCR) and/or the
Surveillance, Epidemiology, and End Results (SEER) Program and meet high-quality data criteria. These registries cover approximately 83% of the US population.
Rates are per 100,000 persons and are age-adjusted to the 2000 US standard population. ‘All histologies’ excludes International Classification of Diseases for
Oncology, 3rd edition (ICD-O-3) histology codes 9050 (mesothelioma), 9140 (Kaposi sarcoma), and 9590-9989 (lymphomas and leukemias). Cervical cancers
were limited to carcinomas only (ICD-O-3 histology codes 8010-8671 and 8940-8941). All other sites were limited to squamous cell carcinomas only (ICD-O-3
histology codes 8050-8084 and 8120-8131). Oral cavity and oropharyngeal cancers were limited to the subsites specified in Table 2.
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the NCI.40 Confidence intervals were based on the
Gamma method and used the modification detailed
by Tiwari et al.41 Rates were calculated by age, race
(white, black, and API), ethnicity (Hispanic or non-
Hispanic), stage, and US Census region (Northeast,
South, East or West) (Fig. 3). The race category la-
beled as ‘all races combined’ and the overall cancer
rates include individuals of all races: white, black,
AI/AN, API, other, and unknown. Other and
unknown categories were not reported on separately,
because denominator information was not available
for these groups; thus, the sum of the individual race
categories (white, black, and API) will not equal the
‘all races combined’ category. Hispanic ethnicity
included individuals from all race categories.
Cancers were staged according to SEER Sum-
mary Stage 1977 (for cases diagnosed before 2001)
and SEER Summary Stage 2000 (for cases diagnosed
in 2001 or later). For some cancer sites, differences
between the 2 staging schemes can result in incon-
sistent staging.42,43 Coding for regional and distant
stages of cancers of the vagina and some oral cavity
and oropharyngeal subsites was not consistent
between the 2 schemes; thus, we reported only early
or late stage for vaginal and oral cavity/oropharyn-
geal cancers. Where early or late stage is reported,
early stage includes localized stage, and late stage
includes regional and distant stages. Certain articles
in this Supplement also examine tumor grade, with
cancer cells classified by the degree of microscopic
abnormality and the likelihood of growth and metas-
tasis.30
RESULTS
This section is intended to provide a general over-
view of the distribution of these cancers in the con-
text of all HPV-associated cancers. Comprehensive
descriptions of each cancer can be found in indivi-
dual articles in this Supplement.29,36,44-47
Table 4 displays age-adjusted cancer incidence
rates for the invasive cancers included in this article
by registry. In total, there were 149,507 cases of inva-
sive HPV-associated cancer from 1998 through 2003.
Cervical carcinomas, as expected, were the most fre-
quent cancers examined in our study, with an aver-
age of 10,846 cases per year, followed by oral cavity
and oropharyngeal SCCs, with an average of 7360
cases per year. The averages were 3018 cases of anal
and rectal SCCs per year and 2266 vulvar SCCs per
year. Penile and vaginal cancers were rare, with aver-
age annual counts of 828 and 601 per year, respec-
tively. The South Atlantic division had the highest
rates of cervical, anal, and oral cavity/oropharyngeal
cancers, whereas the West South Central division had
the highest rates of vaginal and penile cancers. The
East South Central division had the highest rate of vul-
var cancer. Figure 5 displays age-adjusted cancer inci-
dence rates for invasive cancers by Census division.
Rate and percentage distributions of invasive
cancers associated with HPV by sex, cancer site,
age, race, ethnicity, disease stage, and region are
shown in Table 5. There were 104,097 cases of HPV-
associated cancers among women during 1998
through 2003. The median age at diagnosis for cer-
vical carcinoma was 47 years. Other invasive HPV-
associated cancers tended to be diagnosed later,
with a median age >60 years at diagnosis. Approxi-
mately 50% of vaginal and vulvar SCCs were diag-
nosed among women aged 70 years. Black women
had higher rates of invasive cervical carcinoma, and
vaginal SCCs, and oral cavity/oropharyngeal SCCs,
whereas white women had higher rates of vulvar
and anal SCCs. Hispanic women had higher rates of
cervical cancer than non-Hispanic women, whereas
non-Hispanic women had higher rates of oral cavity
and oropharyngeal cancers. All HPV-associated can-
cers among women were diagnosed most often at
the localized stage, with the exception of oral cavity
and oropharyngeal SCCs, which were diagnosed
more frequently at the regional stage. The South
had the highest rates of cervical, vaginal, anal, and
oral cavity/oropharyngeal cancers, whereas the Mid-
west had the highest rate of vulvar cancer.
There were 45,410 cases of HPV-associated can-
cers among men from 1998 through 2003. Among
men, those with invasive anal and oral cavity/oro-
pharyngeal SCCs were younger at diagnosis (median
ages, 57 years and 58 years, respectively) than men
with invasive penile SCCs (median age at diagnosis,
68 years). API men had lower rates of all invasive
HPV-associated cancers, whereas black men had
higher rates of invasive anal and oral cavity/oropha-
ryngeal SCCs. Hispanic men had higher rates of inva-
sive penile SCC, and non-Hispanic men had higher
rates of invasive anal and oral cavity/oropharyngeal
SCCs. Invasive penile and anal SCCs in men were
diagnosed most often at the localized stage. Invasive
oral cavity and oropharyngeal cancers were most
likely to be diagnosed at the regional stage. The rate
of invasive penile SCC was lowest for men in the
West, whereas the rate of invasive anal SCC was low-
est in the Midwest. The rates of invasive oral cavity
and oropharyngeal SCCs among men were highest in
the South.
Among cancers for which both women and men
were at risk, anal cancers were more common among
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women, whereas men had higher rates of oral and
oropharyngeal cancers. Men tended to be diagnosed
with invasive anal and oral cavity/oropharyngeal
SCCs at younger ages than women. White women
had the highest rate of invasive anal SCC, whereas
blacks had the highest rate among men.
Table 6 examines in situ vulvar, vaginal, penile,
anal, and oral cavity/oropharyngeal SCCs by age,
TABLE 4
Average Annual Incidence Counts and Rates of Invasive Cancers Associated With Human Papillomavirus by Registry: United States, 1998-2003*,y
Registry





Count Rate Count Rate Count Rate Count Rate Count Rate Count Rate Count
Alaska 22 7.8 —§ —§ 5 2.0 8 1.7 —§ —§ 18 3.8 55
Alabama 217 9.1 14 0.5 50 2.0 51 1.1 14 0.7 151 3.3 496
Arkansas 145 10.3 9 0.6 24 1.6 39 1.4 15 1.2 99 3.5 331
California 1552 9.2 72 0.4 232 1.4 439 1.4 90 0.7 919 3.0 3304
Colorado 154 7.0 7 0.3 27 1.3 48 1.2 11 0.7 103 2.6 349
Connecticut 134 7.0 9 0.4 44 2.0 39 1.1 16 1.0 112 3.1 354
District of Columbia 37 11.8 3 1.0 5 1.6 13 2.4 —§ —§ 29 5.1 —§
Delaware 38 8.9 3 0.6 9 2.0 8 1.0 —§ —§ 28 3.4 —§
Florida 907 10.3 43 0.4 171 1.6 323 1.7 69 0.8 799 4.3 2311
Hawaii 59 9.2 —§ —§ 6 0.9 9 0.7 —§ —§ 31 2.4 108
Idaho 41 6.6 3 0.4 8 1.3 14 1.1 4 0.8 33 2.7 103
Illinois 640 10.0 30 0.4 121 1.8 146 1.2 41 0.8 389 3.2 1366
Indiana 269 8.6 17 0.5 63 1.9 76 1.3 22 0.8 193 3.2 640
Iowa 123 8.2 9 0.4 41 2.3 32 1.0 13 0.9 78 2.5 295
Kansas 112 8.2 5 0.3 24 1.5 33 1.2 7 0.6 71 2.7 251
Kentucky 230 10.7 12 0.5 47 2.1 55 1.3 24 1.3 138 3.3 506
Louisiana 236 10.4 15 0.6 53 2.3 59 1.4 17 1.0 152 3.5 533
Massachusetts 225 6.4 17 0.4 71 1.8 77 1.2 26 0.9 209 3.2 624
Maine 54 7.5 5 0.6 19 2.4 22 1.5 7 1.1 55 3.8 161
Michigan 420 8.1 30 0.5 110 2.0 111 1.1 35 0.8 317 3.2 1022
Minnesota 167 6.6 12 0.5 52 1.9 44 0.9 21 1.0 126 2.6 421
Missouri 266 9.0 13 0.4 62 1.9 72 1.3 21 0.9 194 3.3 628
Montana 37 7.9 —§ —§ 7 1.3 11 1.1 5 1.1 30 3.1 —§
Nebraska 69 8.1 3 0.3 17 1.6 20 1.1 8 1.1 42 2.4 159
New Jersey 443 9.6 19 0.4 89 1.8 101 1.1 32 0.9 260 3.0 945
New Mexico 73 7.9 5 0.5 13 1.4 22 1.2 5 0.7 36 2.0 154
New York 925 8.9 49 0.4 190 1.7 265 1.4 67 0.8 535 2.8 2031
Ohio 493 8.2 30 0.5 130 1.9 138 1.2 34 0.7 343 2.9 1168
Oklahoma 170 9.7 10 0.5 36 1.9 50 1.4 14 0.9 111 3.2 390
Oregon 137 7.7 9 0.4 36 1.8 56 1.6 10 0.6 118 3.3 366
Pennsylvania 568 8.5 39 0.5 157 1.9 158 1.2 45 0.8 430 3.2 1396
Rhode Island 42 7.3 3 0.4 16 2.4 16 1.4 5 0.9 31 2.8 111
South Carolina 209 9.8 12 0.5 44 2.0 47 1.2 15 0.9 156 3.8 482
Texas 1018 10.0 55 0.6 144 1.5 240 1.3 78 1.0 551 3.0 2086
Utah 59 6.2 3 0.3 12 1.4 18 1.1 4 0.5 32 1.9 128
Vermont 28 8.4 3 0.7 7 2.0 5 0.8 3 1.0 18 2.7 64
Washington 213 7.0 12 0.4 53 1.7 76 1.3 16 0.6 184 3.2 552
Wisconsin 211 7.7 13 0.4 53 1.7 50 0.9 17 0.7 170 3.1 513
West Virginia 110 10.9 8 0.6 22 1.9 31 1.5 11 1.1 69 3.3 250
Average annual total 10,846 8.9 601 0.5 2266 1.7 3018 1.3 828 0.8 7360 3.1 24,918
No. for 1998-2003 65,074 3604 13,597 18,105 4967 44,160 149,507
*Only carcinomas are included for cervical cancers. Only squamous cell carcinomas (SCCs) are included for vulvar, vaginal, penile, anal and oral cavity/oropharyngeal cancers. All histologies were microscopi-
cally confirmed.
yData are from population-based cancer registries that participate in the National Program of Cancer Registries and/or the Surveillance, Epidemiology, and End Results Program and meet high-quality data cri-
teria. These registries cover approximately 83% of the US population. Rates are per 100,000 persons and are age-adjusted to the 2000 US standard population.
{Anal cancers include SCCs coded to the rectum. Oral cavity and oropharyngeal cancers are limited to the subsites specified in Table 2.
§Indicates that the cell was suppressed because the average annual count was <3 during the 6-year period.
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race, ethnicity, and region. There were 15,593 non-
cervical in situ cancers that were considered to be
HPV-associated from 1998 through 2003; 11,379 of
those cancers were diagnosed in women, and 4214
were diagnosed in men. Generally, the patterns were
similar to those observed for invasive disease.
Data Limitations
Cancer registry data do not contain information on
the presence of HPV in tumor tissue. To minimize
this limitation, we chose sites with an established
HPV association and limited our analyses by histol-
ogy and microscopic confirmation. Case-level data
on other risk factors for these cancers, such as smok-
ing and high parity, also are not available from can-
cer registries. We excluded registries that did not
meet USCS standards for data quality and timeliness
for any year during 1998 through 2003; thus, these
data do not cover the entire population of the United
States. A lower proportion of the population was
included from the South (63%) than from any other
US Census region because of the exclusion of more
registries from this region. However, an analysis of
cervical cancer that included more states from the
South but was limited to more recent years revealed
that the rates in this region remained significantly
increased compared with other regions.45 Thus, we
believe that differences between the South and other
FIGURE 5. Rates of invasive human papillomavirus-associated cancers by US Census Division. Only carcinomas are included for cervical cancers. Only squa-
mous cell carcinomas (SCCs) are included for vulvar, vaginal, penile, anal and oral cavity/oropharyngeal cancers. All histologies were confirmed microscopically.
Data are from population-based cancer registries that participate in the National Program of Cancer Registries and/or the Surveillance, Epidemiology, and End
Results Program and meet high-quality data criteria. These registries cover approximately 83% of the US population. Rates are per 100,000 persons and are
age-adjusted to the 2000 US standard population. Note that the rate scale varies by cancer site. These maps were developed by James Cucinelli (IMS, Inc.)
and Dave Stinchcomb (National Cancer Institute) based on the micromaps design.
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regions are representative and are not an artifact of
lower population coverage in the South. There are
several limitations concerning the collection of in
situ tumors that may have influenced our analyses.
Although NPCR and SEER require reporting of in situ
tumors, the quality of the data is not as consistent as
the quality of the data for invasive cancers.31
In summary, this Supplement represents our first
attempt to assess the overall burden of HPV-asso-
ciated cancers in the United States. The available
data cover the majority of the US population. This
comprehensive analysis sets the stage for monitoring
the impact of the HPV vaccine and potential tempo-
ral and geographic changes in HPV-associated dis-
ease burden. By using population-based cancer
registries, the ABHACUS Supplement has achieved its
main purposes: assessing the current (prevaccine)
burden of HPV-associated cancers and providing a
baseline for monitoring future trends in these can-
cers. Histology categories are described comprehen-
sively and are based on current knowledge. In
addition, the focus on histologic-specific analyses
and rare cancer sites should benefit planning for
future etiological and clinical studies, as well as vac-
TABLE 5
Invasive Cancers Associated With Human Papillomavirus by Selected Characteristics: United States, 1998-2003*,y
Feature
Female Male







Rate % Rate % Rate % Rate % Rate % Rate % Rate % Rate %
Overall 8.9 100 1.7 100 0.5 100 1.5 100 1.3 100 0.8 100 1.0 100 5.2 100
Median age, y 47 69 70 62 64 68 57 58
Age, y
<30 1.4 6.3 <0.1 0.7 <0.1 0.5 <0.1 0.3 <0.1 0.5 <0.1 0.4 <0.1 0.6 <0.1 0.2
30-39 13.5 22.1 0.7 5.5 0.1 3.4 0.4 3.7 0.3 2.7 0.2 3.7 0.6 9.7 0.7 2.0
40-49 15.8 26.3 1.8 14.2 0.4 10.5 1.9 17.8 1.2 12.4 0.5 9.6 1.4 23.3 5.8 18.3
50-59 14.5 18.0 2.5 14.6 0.7 15.6 3.3 22.8 2.9 23.3 1.1 16.9 1.9 22.6 14.8 33.6
60-69 14.8 12.5 3.7 15.1 1.3 19.3 4.3 20.1 4.8 26.0 2.5 24.4 2.6 19.6 18.0 25.6
70 12.3 14.8 8.4 49.9 2.3 50.7 5.2 35.3 4.7 35.3 4.5 44.9 3.1 24.2 13.1 20.3
Race
White 8.4 79.1 1.8 90.7 0.4 82.2 1.6 89.9 1.3 87.1 0.8 88.3 1.0 85.6 5.1 86.5
Black 12.6 14.5 1.3 6.9 0.7 14.0 1.3 7.8 1.5 10.5 0.8 7.8 1.2 11.4 6.8 11.1
API 8.3 3.9 0.4 0.7 0.3 2.0 0.4 1.0 0.5 1.3 0.4 1.4 0.2 0.7 1.7 1.1
Ethnicity
Non-Hispanic 8.4 84.2 1.8 95.0 0.4 90.9 1.5 92.8 1.4 96.0 0.8 87.3 1.0 93.4 5.3 94.8
Hispanic 14.2 15.8 1.3 5.0 0.6 9.1 1.5 7.2 0.7 4.0 1.3 12.7 0.8 6.6 3.6 5.2
Stage{
Localized 4.7 52.3 1.1 62.4 0.2 44.4 0.8 51.2 0.3 22.4 0.5 62.4 0.5 53.7 0.8 15.3




0.2 27.7 0.3 25.1
4.0 77.9
Distant 0.8 9.1 0.1 3.4 0.1 8.2 0.0 3.2 0.1 6.5
Unstaged 0.6 7.1 0.1 5.9 0.1 13.6 0.2 15.0 0.1 7.4 0.1 6.7 0.2 14.7 0.4 6.8
Region 15.3
Northeast 8.4 22.3 1.8 26.2 0.4 23.7 1.4 21.9 1.3 23.6 0.9 24.2 1.0 23.8 4.9 22.0
Midwest 8.5 25.5 1.9 29.6 0.4 26.9 1.4 24.9 1.3 26.0 0.8 26.5 0.8 22.1 5.0 26.1
South 10.1 30.6 1.7 26.6 0.5 30.4 1.7 30.9 1.5 30.0 0.9 31.4 1.1 29.4 5.9 31.3
West 8.5 21.6 1.4 17.5 0.4 19.0 1.6 22.3 1.3 20.3 0.7 18.0 1.1 24.7 4.7 20.5
API indicates Asian/Pacific Islander.
*Data are from population-based cancer registries that participate in the National Program of Cancer Registries and/or the Surveillance, Epidemiology, and End Results (SEER) Program and meet high-quality
data criteria (see Table 4 for a list of registries). These registries cover approximately 83% of the population for the period studied.
yThe data represent incidence rates and % distribution of cases unless otherwise specified. Rates are per 100,000 persons and are age-adjusted to the 2000 US standard population. Hispanic origin is not
mutually exclusive from race categories (white, black, API). Rates could not be calculated for individuals of other or unknown race/ethnicity; thus, percentage distributions for race categories do not total 100%.
Only microscopically confirmed cervical carcinomas and squamous cell carcinomas (SCCs) for other sites were examined.
{SEER Summary Stage 1977 was used for cancers diagnosed from 1998 through 2000, and SEER Summary Stage 2000 was used for cancers diagnosed from 2001 through 2003. Stage for vagina and some oral
cavity and oropharyngeal subsites are not considered comparable between these staging schemes, so regional and distant stage were combined to make the 2 schemes comparable.
§Regional and distant stage have been combined for cancers of the vagina and oral cavity/oropharynx.
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cine interventions, by providing a critical baseline
assessment of the population burden of HPV-asso-
ciated malignancy. It is our hope that, with current
population-based cancer registries covering 100% of
the US population since 1998, we will be in a posi-
tion to monitor changes in the burden of in situ and
invasive HPV-associated cancers with more accuracy
and precision.21,48
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